

Learner Notification

Total Health Conferencing
New and Supporting Data for Optimizing Therapy in HER2+ Breast Cancer
June 26, 2021
Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Amedco LLC designates this live activity for a maximum of .75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of .75 ANCC contact hours.

Pharmacists and Pharmacy Technicians

Amedco LLC designates this activity for a maximum of .75 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-21-124-L04-P

NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives - After Attending This Program You Should Be Able To

1. Review neoadjuvant and adjuvant treatment strategies in HER2 positive breast cancer
2. Review and discuss the unmet need of brain metastasis in HER2 positive breast cancer
3. Review existing and newly approved treatment options in the metastatic setting like trastuzumab deruxtecan, tucatinib and agents in development

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First	Last	Commercial Interest
Nusayba	Bagegni	AstraZeneca :Research Grant Site Principal Investigator, Daiichi Sankyo :Research Grant Site Principal Investigator
William	Gradishar	NA

How to Get Your Certificate

1. CME Link: <https://workshop-evaluator.herokuapp.com/evaluation/9143>
2. Evaluate the meeting.
3. Print all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com